Cerevel Therapeutics to Report Fourth Quarter and Full Year
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to
Globe Newswire1-02-2023, 18:39
EAACI Congress 2025 - Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future 18-03-2025, 15:00